Guoshuai Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guoshuai Cao has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Jun Huang
Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA
16 shared publications - Yifei Hu
Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA
15 shared publications - Michael R. Bishop
University of Chicago, Chicago, Illinois, United States
14 shared publications - Nicholas W. Asby
University of Chicago 1 Pritzker School of Molecular Engineering Chicago, Illinois
14 shared publications - Peter A. Riedell
David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL
14 shared publications - Duy-Thuc Nguyen
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea
13 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Transcriptomic analysis of T cells in discovery dataset.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Transcriptomic analysis of T cells in discovery dataset.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Survival of mice and tumor burden in OCI-Ly8 model following CAR T-cell engraftment.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Survival of mice and tumor burden in OCI-Ly8 model following CAR T-cell engraftment.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). However, up to 60% of patients do not achieve a complete response. To uncover determinants of therapeutic efficacy, we analyzed the infusion products (IPs) of eight r/r DLBCL patients with distinct clinical responses to axicabtagene ciloleucel using single-cell transcriptomics. Compared with patients who exhibited progressive disease, IPs of complete responders demonstrated enriched signatures of type I interferon (IFN-I) signaling. Based on these findings, we developed a strategy to improve CD19-directed CAR T-cell treatment efficacy by incorporating IFN-I as an enhancer during the ex vivo manufacturing process, with IFN-I removal before CAR T-cell infusion to avoid in vivo toxicities. For both CD28- and 4-1BB–costimulated second-generation CARs, we found that low-strength IFN-I signaling enhanced CAR T-cell cytotoxicity and treatment efficacy against B-cell lymphoma and leukemia. Our low-strength IFN-I–enhanced CAR T-cell ex vivo manufacturing approach leverages an existing FDA-approved pharmacologic agent, circumvents in vivo interferon–associated toxicities, and remains fully compatible with current CAR constructs and manufacturing workflows. Together, our results establish IFN-I as a potent and costimulation-independent enhancer of CAR T-cell efficacy and provide a translationally feasible approach to enhance CAR T-cell therapies.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). However, up to 60% of patients do not achieve a complete response. To uncover determinants of therapeutic efficacy, we analyzed the infusion products (IPs) of eight r/r DLBCL patients with distinct clinical responses to axicabtagene ciloleucel using single-cell transcriptomics. Compared with patients who exhibited progressive disease, IPs of complete responders demonstrated enriched signatures of type I interferon (IFN-I) signaling. Based on these findings, we developed a strategy to improve CD19-directed CAR T-cell treatment efficacy by incorporating IFN-I as an enhancer during the ex vivo manufacturing process, with IFN-I removal before CAR T-cell infusion to avoid in vivo toxicities. For both CD28- and 4-1BB–costimulated second-generation CARs, we found that low-strength IFN-I signaling enhanced CAR T-cell cytotoxicity and treatment efficacy against B-cell lymphoma and leukemia. Our low-strength IFN-I–enhanced CAR T-cell ex vivo manufacturing approach leverages an existing FDA-approved pharmacologic agent, circumvents in vivo interferon–associated toxicities, and remains fully compatible with current CAR constructs and manufacturing workflows. Together, our results establish IFN-I as a potent and costimulation-independent enhancer of CAR T-cell efficacy and provide a translationally feasible approach to enhance CAR T-cell therapies.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Transcriptomic analysis of T cell in validation dataset.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Transcriptomic analysis of T cell in validation dataset.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Expression of ISGs with IFN-α2 signaling.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Expression of ISGs with IFN-α2 signaling.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
CAR T-cell cytotoxicity on VAL cells and persistence after tumor stimulation.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
CAR T-cell cytotoxicity on VAL cells and persistence after tumor stimulation.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Type I interferon receptor expression and IFN-α2 titration in CAR T cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Type I interferon receptor expression and IFN-α2 titration in CAR T cells.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Patient characteristics and relevant clinical data.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Patient characteristics and relevant clinical data.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Sequences of the two CAR inserts.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Sequences of the two CAR inserts.